CRXT Stock Price is back at it again, good gains! URGENT Report

CRXT stock price

Clarus Therapeutics Holdings Inc. CRXT Stock Price is up 14% in a month...

Stay Ahead of the
Stock Market Game!
Subscribe to Small Cap
Exclusive for more


BTTX Stock Price is up 23%, can it go higher? URGENT
Here's Who Just Picked Up Photomedex Inc (NASDAQ:PHM...
Catch Peregrine Pharmaceuticals (NASDAQ:PPHM) Shares...

Clarus Therapeutics Holdings Inc. CRXT Stock Price is up 14% in a month and 10% over the last 5 days.

Volume is interesting because it is down 65% but still up, very good sign actually.

Before we do, remember to stop what you are doing and 👇 Sign up for our newsletter to get the latest breakout stocks and trending stocks!

[thrive_leads id=’14274′]

Before we get started, I wanted to introduce myself to you. Hi 🙋‍♂️ I’m Alexander Goldman and I have been successfully trading breakout stocks and trending stocks for two decades now.

I’m now helping traders find breakout stocks. My claim to fame is the expert at finding trending stocks.

What do I mean by big winners?

Stocks that move more than 100% in a month! CRXT Stock Price could?

Does that always happen, NO! But, I’m very good! Take a look at this article I wrote, where I called 5 stocks, 3 losers and 2 winners and they all did what I thought!

The article is HERE where I shine a spotlight on trending stocks and breakout stocks!

Now, let’s go over some of the basic information on this stock before we get in the technical analysis

Clarus Therapeutics Holdings Inc. Company Information

Company Name: Clarus Therapeutics Holdings Inc.

Ticker: CRXT

Exchange: NASDAQ


Clarus Therapeutics Holdings Company Summary:

Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. the company’s first commercial product is JATENZO. It is headquartered in Northbrook, IL.

Clarus Therapeutics stock price is due to News?

June 09, 2022

Announced that new data for JATENZO (testosterone undecanoate) will be presented in the form of an abstract at ENDO 2022, the Endocrine Society’s annual meeting, taking place at the Georgia World Congress Center in Atlanta June 11-14, 2022.

March 16, 2022

Announced the initiation of screening for the first patient in an investigator-initiated Phase 4 clinical trial designed to evaluate the efficacy and safety of JATENZO (testosterone undecanoate) oral softgel capsules for the treatment of adult hypogonadal men with chronic kidney disease (CKD). Clarus expects to announce results from the trial in the first half of 2023.

CRXT 5 Day Chart


CRXT Stock Price Technical Analysis:

Let’s go over 4 critical factors in regards to a trending stock.

The volume, which is basically demand of a stock is not consistent! In fact, it is down big right now, the good news it’s still up.

The news, is about as good as you can get!

The chart, it is bullish but it went up 85% in today and is now pulling back.

The fundamentals, the vertical is a very profitable one!

I believe Clarus Therapeutics stock could be a good one but not right now. I’m putting it on my watchlist and getting familiar with it, waiting for the right time. After this pullback it will consolidate and I will be watching it!

Sign up for our newsletter 👇👇👇 to get the latest HOT stocks and trending stocks!

[thrive_leads id=’14274′]

Stay in the lopp :

Carbo Industries Picked Up Sprague Resources ...
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Sprague Resources Lp (NYSE:SRLP) reported that Carbo Industries, Inc. has
Is Healthier Choices Management (HCMC) Stock ...

Over the course of the past months, there had been a certain degree of excitement about the patent infringement lawsuit that had been

Heartland Advisors Inc. is Buying Intricon Co...
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Intricon Corp (NASDAQ:IIN) reported that Heartland Advisors Inc. has picked

related post

Skip to content